Jian-liang Yang

发表

Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.

Yuankai Shi, Y. Chi, Jian-liang Yang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Phase I study of chimeric anti-CD20 monoclonal antibody in Chinese patients with CD20-positive non-Hodgkin's lymphoma

P. Liu, Yuankai Shi, Weijing Zhang, 2016, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy

P. Liu, Yuankai Shi, Ning Li, 2014, Cancer Chemotherapy and Pharmacology.

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients

P. Xing, Yuankai Shi, Dan Wang, 2020, Theranostics.

Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2013, Medical Oncology.

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Cancer management and research.

A new prognostic model including platelet/lymphocyte ratio and International Prognostic Score 3 for freedom from progression in patients with previously untreated advanced classical Hodgkin lymphoma

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Asia-Pacific journal of clinical oncology.

Prognostic value of pretreatment serum beta-2 microglobulin level in advanced classical Hodgkin lymphoma treated in the modern era

P. Liu, Yuankai Shi, Jian-liang Yang, 2016, Oncotarget.

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.

Peng Liu, Haifeng Song, Yuankai Shi, 2020, European journal of cancer.

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

P. Liu, Jian-liang Yang, Sheng Yang, 2022, BMC cancer.

Dismal outcome of relapsed or primary refractory adult T‐cell lymphoblastic lymphoma: A retrospective study from China

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Asia-Pacific journal of clinical oncology.

Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Annals of Hematology.

Long‐term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single‐center retrospective study

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Asia-Pacific journal of clinical oncology.

Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type

P. Liu, P. Xing, Yuankai Shi, 2017, Annals of Hematology.

GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

P. Liu, Yuankai Shi, Ye-Xiong Li, 2016, Medicine.

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.

P. Liu, Yuankai Shi, Weihu Wang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Chinese a Nti鄄 Cancer a Ssociation

P. Liu, Yuankai Shi, L. Xue, 2022 .

Absolute monocyte count is a prognostic indicator in a patient with diffuse large B-cell lymphoma after autologous peripheral blood stem cell transplant

Peng Liu, Yuankai Shi, Jian-liang Yang, 2015, Leukemia & lymphoma.

Abnormal pretreatment coagulation factor levels correlate with poor prognosis in patients with early-stage extranodal nasal-type natural/killer T cell lymphoma

Y. Chai, S. Qi, Yexiong Li, 2020, Annals of Hematology.

Low CCL19 Expression Is Associated With Adverse Clinical Outcomes For Patients With Advanced Stage Follicular Lymphoma

N. Lou, P. Liu, Yuankai Shi, 2021 .

CMAR_A_269624 11515..11522

P. Liu, Jian-liang Yang, Sheng Yang, 2020 .

The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Asia-Pacific journal of clinical oncology.

Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified

P. Liu, Yuankai Shi, Weihu Wang, 2017, Annals of Hematology.

Evaluation of serum high sensitive C-reactive protein , procalcitonin , neopterin and leukocyte on different respiratory infectious disease in Chinese children

Hanrong Cheng, Dong-Cai Li, Li Chen, 2016 .

Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.

P. Liu, Shulian Wang, Ye-Xiong Li, 2018, International journal of radiation oncology, biology, physics.

Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicity

P. Liu, Yuankai Shi, Jian-liang Yang, 2017, Asia-Pacific journal of clinical oncology.

Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2015, Chinese journal of cancer.

Oral topotecan: Bioavailability, pharmacokinetics and impact of ABCG2 genotyping in Chinese patients with advanced cancers.

Yuankai Shi, Ning Li, Jian-liang Yang, 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era

P. Liu, Shulian Wang, H. Fang, 2019, Leukemia & lymphoma.

Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005–2018)

P. Liu, Yuankai Shi, H. Fang, 2022, Cancer Pathogenesis and Therapy.

Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Chronic diseases and translational medicine.

Survival and pretreatment prognostic factors for extensive‐stage small cell lung cancer: A comprehensive analysis of 358 patients

Junling Li, Yuankai Shi, Yan Wang, 2021, Thoracic cancer.

Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma.

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Future oncology.

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy

N. Lou, P. Xing, Yuankai Shi, 2021, Cancer Immunology, Immunotherapy.

Development of new prognostic model based on pretreatment βLRI and LLRI for stage IE/IIE upper aerodigestive tract ENKTL, nasal type

P. Liu, Yuankai Shi, Jian-liang Yang, 2017, Oncotarget.

Absolute bioavailability studies of a new oral topotecan formulation in Chinese patients using UHPLC-MS/MS.

Yuankai Shi, Ning Li, Jian-liang Yang, 2013, Journal of pharmaceutical and biomedical analysis.

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

P. Liu, P. Xing, Yuankai Shi, 2016, Hematology.

In vitro study on cryopreservation of peripheral blood stem cells with uncontrolled freezer

Yuankai Shi, P. Liu, Jian-liang Yang, 2002 .

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma

D. Lin, Peng Liu, P. Xing, 2019, Front. Oncol..

Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients

P. Liu, Yuankai Shi, L. Xue, 2008, International journal of hematology.

Effect of JS001, a monoclonal antibody targeting programed death-1 (PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

P. Liu, Yuankai Shi, Jian-liang Yang, 2018 .

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2019, Journal of Translational Medicine.

Phase II trial of paclitaxel‐carboplatin with intercalated gefitinib for untreated, epidermal growth factor receptor gene mutation status unknown non‐small cell lung cancer

Junling Li, Yuankai Shi, X. Hao, 2014, Thoracic cancer.

[Evaluation of the role of rhIL-11 on hematological recovery in lymphoma patients after autologous hematopoietic stem cell transplantation].

P. Liu, Yuankai Shi, Jian-liang Yang, 2012, Zhonghua zhong liu za zhi [Chinese journal of oncology].

Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis.

Guan-qing Wu, P. Liu, Yuankai Shi, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14‐year experience of a single‐center study

P. Liu, Yuankai Shi, Lingdi Zhao, 2012, Journal of clinical apheresis.

Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib

Peng Liu, Yuankai Shi, Biao Liu, 2020, Targeted Oncology.

Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Molecular Diagnosis & Therapy.

Chinese a Nti鄄 Cancer a Ssociation

Feng, P. Liu, P. Liu, 2022 .

R‐CHOP immunochemotherapy plus surgery is associated with a superior prognosis in Chinese primary intestinal diffuse large B‐cell lymphoma

Yuankai Shi, P. Liu, Xin Wang, 2020, Asia-Pacific journal of clinical oncology.

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy

N. Lou, P. Liu, Yuankai Shi, 2021, Journal of Translational Medicine.

Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphoma.

P. Liu, Yuankai Shi, Jian-liang Yang, 2014, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China

P. Liu, Yuankai Shi, Shulian Wang, 2019, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens

P. Liu, Yuankai Shi, Jian-liang Yang, 2020, Journal of Cancer.

Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay.

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2021, Journal of pharmaceutical and biomedical analysis.

The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era.

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Leukemia research.

Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.

P. Liu, Yuankai Shi, Jian-liang Yang, 2019, The oncologist.

A prognostic nomogram constructed for relapsed or refractory diffuse large B‐cell lymphoma patients

P. Liu, Yuankai Shi, Jian-liang Yang, 2019, Asia-Pacific journal of clinical oncology.

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study

Zhi-xiang Shen, Jie Jin, Wei Li, 2021, Chinese medical journal.

Decreased Prognostic Value of International Prognostic Score in Chinese Advanced Hodgkin Lymphoma Patients Treated in the Contemporary Era

P. Liu, Yuankai Shi, Jian-liang Yang, 2016, Chinese medical journal.

The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.

Peng Liu, Yuankai Shi, Jian-liang Yang, 2014, Leukemia research.

MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma

P. Liu, T. Qiu, Jian-liang Yang, 2023, Journal of Cancer Research and Clinical Oncology.

Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis

P. Liu, Jian-liang Yang, Sheng Yang, 2015, Medical Oncology.

[Differences between clinical response and pathologic response of breast cancer after neoadjuvant chemotherapy].

L. Xue, S. Zou, Ren-zhi Zhang, 2010, Zhonghua bing li xue za zhi = Chinese journal of pathology.

Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Leukemia & lymphoma.

Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)

Fei Li, Heming He, Yongping Song, 2022, Blood.

A phase 1 trial of JS001, a monoclonal antibody targeting programmed death-1 (PD-1) in patients with advanced or recurrent malignancies.

Haifeng Song, Yuankai Shi, Jian-liang Yang, 2017 .

Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China

P. Liu, P. Xing, Jian-liang Yang, 2019, BMJ Open.

Efficacy and Safety of Gemcitabine-Based Combination Regimens in Patients with Extranodal Natural Killer/T Cell Lymphoma, Nasal Type

Yuankai Shi, L. Qiu, Weihu Wang, 2014 .

[Clinicopathological features and outcomes: analysis of 21 cases of lymphoma in pregnancy].

P. Liu, Yuankai Shi, P. Yuan, 2015, Zhonghua yi xue za zhi.

[Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2005, Ai zheng = Aizheng = Chinese journal of cancer.

Efficacy and safety of PD‐1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients

P. Liu, Jian-liang Yang, Sheng Yang, 2023, European journal of haematology.

Combined effect of histone deacetylase inhibitor suberoylanilide hydroxamic acid and anti-CD20 monoclonal antibody rituximab on mantle cell lymphoma cells apoptosis.

Yuankai Shi, Jian-liang Yang, Xiaohong Han, 2012, Leukemia research.

A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2015, Leukemia & lymphoma.

Different clinical characteristics and treatment strategies for patients with localized sinonasal diffuse large B cell lymphoma and extranodal NK/T cell lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2017, Journal of Hematology & Oncology.

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2019, Journal of Translational Medicine.

Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study

Jian-liang Yang, Shengyu Zhou, Q. Zhong, 2023, Annals of hematology.

Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Cancer biology & medicine.

Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.

Yuankai Shi, Y. Chi, Jian-liang Yang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma

D. Lin, P. Xing, Junling Li, 2019, Front. Oncol..